Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (611) Arrow Down
Filter Results: (611) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,026)
    • People  (4)
    • News  (257)
    • Research  (611)
    • Events  (9)
    • Multimedia  (24)
  • Faculty Publications  (398)

Show Results For

  • All HBS Web  (1,026)
    • People  (4)
    • News  (257)
    • Research  (611)
    • Events  (9)
    • Multimedia  (24)
  • Faculty Publications  (398)
← Page 4 of 611 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • November 2009 (Revised March 2010)
  • Case

Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story

By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details
Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States
Citation
Educators
Purchase
Related
Hamermesh, Richard G., Raju Kucherlapati, and Rachel Gordon. "Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story." Harvard Business School Case 810-066, November 2009. (Revised March 2010.)
  • 1996
  • Chapter

Eli Lilly and Company: Drug Development Strategy

By: S. Thomke, A. Nimgade and P. Pospisil
Keywords: Product Development; Corporate Strategy; Pharmaceutical Industry
Citation
Related
Thomke, S., A. Nimgade, and P. Pospisil. "Eli Lilly and Company: Drug Development Strategy." In Strategic Management of Technology and Innovation. 2nd ed. by R. Burgelman, M. A. Maidique, and S. C. Wheelwright. Burr Ridge, IL: Irwin/McGraw-Hill, 1996.
  • 28 Mar 2023
  • Research & Ideas

The FDA’s Speedy Drug Approvals Are Safe: A Win-Win for Patients and Pharma Innovation

Early in the COVID-19 pandemic, the US Food and Drug Administration faced the task of convincing a skeptical public of the safety of new vaccines when the agency began authorizing them for emergency use less than a year after the pandemic... View Details
Keywords: by Kasandra Brabaw; Pharmaceutical
  • October 2000 (Revised March 2003)
  • Case

Merck & Company: Evaluating a Drug Licensing Opportunity

By: Richard S. Ruback and David B Krieger
This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of... View Details
Keywords: Decision Making; Cost vs Benefits; Opportunities; Valuation; Outcome or Result; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Ruback, Richard S., and David B Krieger. "Merck & Company: Evaluating a Drug Licensing Opportunity." Harvard Business School Case 201-023, October 2000. (Revised March 2003.)
  • Research Summary

Physician vs. Patient Incentives in Prescription Drug Choice

The market for medical care involves interactions among patients, providers, and the insurers who pay for the care of their enrollees.  The division of responsibilities creates scope for agency costs and moral hazard in the physician's treatment choice.... View Details
  • September 2019 (Revised October 2019)
  • Case

Aura Biosciences: Bringing a Breakthrough Drug to Market

By: Robert J. Dolan and Navid Mojir
Citation
Educators
Purchase
Related
Dolan, Robert J., and Navid Mojir. "Aura Biosciences: Bringing a Breakthrough Drug to Market." Harvard Business School Case 520-032, September 2019. (Revised October 2019.)
  • February 2006 (Revised August 2006)
  • Case

deCODE Genetics: Hunting for Genes to Develop Drugs

By: Debora L. Spar
In 1996, Kari Stefansson launched a new kind of biotechnology company and a whole new way of attacking diseases. Based in Iceland, his firm, deCODE Genetics, plans to identify the individual genetic markers that lead to society's most prevalent diseases. To do so, it... View Details
Keywords: Information; Innovation Strategy; Genetics; Ethics; Health Disorders; Biotechnology Industry; Iceland
Citation
Educators
Purchase
Related
Spar, Debora L., and Chris Bebenek. "deCODE Genetics: Hunting for Genes to Develop Drugs." Harvard Business School Case 706-040, February 2006. (Revised August 2006.)
  • June 2001
  • Supplement

Merck & Company: Evaluating a Drug Licensing Opportunity

By: Richard S. Ruback
Spreadsheet to (9-201-023). Download only. View Details
Citation
Purchase
Related
Ruback, Richard S. "Merck & Company: Evaluating a Drug Licensing Opportunity." Harvard Business School Spreadsheet Supplement 201-707, June 2001.
  • 09 Feb 2024
  • HBS Case

Slim Chance: Drugs Will Reshape the Weight Loss Industry, But Habit Change Might Be Elusive

what may at first blush appear to be an easier fix: new drugs such as Ozempic, Wegovy, and Mounjaro, says Harvard Business School Professor Regina E. Herzlinger, who has studied the American health care system for decades. Wegovy has been... View Details
Keywords: by Lane Lambert; Health; Pharmaceutical
  • June 1992
  • Teaching Note

Novel Combination of Two Drugs (B) and (C) and Technology Transfer Anti-Inflammatory Drug (B) and (C), Teaching Note

By: Regina E. Herzlinger
Keywords: Innovation and Invention; Technology; Pharmaceutical Industry
Citation
Related
Herzlinger, Regina E. "Novel Combination of Two Drugs (B) and (C) and Technology Transfer Anti-Inflammatory Drug (B) and (C), Teaching Note." Harvard Business School Teaching Note 192-124, June 1992.
  • December 2009 (Revised April 2010)
  • Teaching Note

GlaxoSmithKline: Reorganizing Drug Discovery (TN) (A) and (B)

By: Robert S. Huckman
Teaching Note for [605074] and [605075]. View Details
Keywords: Restructuring; Health; Pharmaceutical Industry
Citation
Purchase
Related
Huckman, Robert S. "GlaxoSmithKline: Reorganizing Drug Discovery (TN) (A) and (B)." Harvard Business School Teaching Note 610-044, December 2009. (Revised April 2010.)
  • 2000
  • Chapter

Measuring Competence? Exploring Firm Effects in Drug Discovery

By: Rebecca M. Henderson and Iain Cockburn
Keywords: Competency and Skills; Measurement and Metrics; Research and Development; Innovation and Invention; Pharmaceutical Industry
Citation
Find at Harvard
Read Now
Related
Henderson, Rebecca M., and Iain Cockburn. "Measuring Competence? Exploring Firm Effects in Drug Discovery." Chap. 6 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter. New York: Oxford University Press, 2000.
  • December 1997 (Revised September 2002)
  • Supplement

Eli Lilly and Company: Drug Development Strategy (B)

By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case. View Details
Citation
Purchase
Related
Thomke, Stefan H., and Ashok Nimgade. "Eli Lilly and Company: Drug Development Strategy (B)." Harvard Business School Supplement 698-026, December 1997. (Revised September 2002.)
  • October 1987 (Revised March 1992)
  • Supplement

Boston Fights Drugs (B): Converting Research to Action

By: V. Kasturi Rangan and Jennifer Lawrence
Describes the results of the advertising pre-test described in the (A) case. The group must now decide how to implement its findings for maximum impact. View Details
Keywords: Advertising; Welfare; Strategy; Advertising Industry; Boston
Citation
Purchase
Related
Rangan, V. Kasturi, and Jennifer Lawrence. "Boston Fights Drugs (B): Converting Research to Action." Harvard Business School Supplement 588-032, October 1987. (Revised March 1992.)
  • November 2018
  • Case

Aura Biosciences: Bringing a Breakthrough Drug to Market

By: Robert J. Dolan and Navid Mojir
Citation
Educators
Related
Dolan, Robert J., and Navid Mojir. "Aura Biosciences: Bringing a Breakthrough Drug to Market." Harvard Business School Case 519-042, November 2018.
  • Article

Measuring Competence? Exploring Firm Effects in Drug Discovery

By: Rebecca M. Henderson and Ian Cockburn
Keywords: Measurement and Metrics; Competency and Skills; Health
Citation
Find at Harvard
Read Now
Related
Henderson, Rebecca M., and Ian Cockburn. "Measuring Competence? Exploring Firm Effects in Drug Discovery." Strategic Management Journal 15 (Winter 1994): 63–84. (Winner of Dan and Mary Lou Schendel Best Paper Prize To honor substantial work published in the Strategic Management Journal presented by Strategic Management Society​.)
  • November 2018
  • Case

David Hysong and SHEPHERD Therapeutics

By: Ananth Raman, John Masko and Aldo Sesia
In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his... View Details
Keywords: Cancer; Therapeutics; Drugs; Health Care and Treatment; Business Startups; Product Development; Financing and Loans; Growth and Development Strategy; Problems and Challenges
Citation
Educators
Related
Raman, Ananth, John Masko, and Aldo Sesia. "David Hysong and SHEPHERD Therapeutics." Harvard Business School Case 619-012, November 2018.
  • 08 Mar 2018
  • Cold Call Podcast

Could a New Business Model Make Clinical Drug Trials More Accessible to Patients?

Keywords: Health
  • December 19, 2018
  • Article

It's Time to Reform the Orphan Drug Act

By: Nicholas Bagley, Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
Citation
Find at Harvard
Read Now
Purchase
Related
Bagley, Nicholas, Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern. "It's Time to Reform the Orphan Drug Act." NEJM Catalyst (December 19, 2018).
  • August 2012 (Revised August 2024)
  • Case

ABC Pharmaceuticals

By: Regina E. Herzlinger and Erik R. Sparks
This case asks students to price a new drug that is in Stage II of its clinical trials. It contains detailed estimates of the time required and costs for all the steps needed to commercialize a drug in the U.S. Students will learn virtually all the steps required to... View Details
Keywords: Drug Development; Price; Product; Product Launch; Health Industry; Technology Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Herzlinger, Regina E., and Erik R. Sparks. "ABC Pharmaceuticals." Harvard Business School Case 313-041, August 2012. (Revised August 2024.)
  • ←
  • 4
  • 5
  • …
  • 30
  • 31
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.